GLP-1 Daily: Ozempic & Wegovy News
South Africa's Regulator Says Bulk Compounders Are Manufacturing; Belgium Won't Pay for Mounjaro in Obesity; Who Started the Wegovy Pill
Monday, October 26, 2026 · 7 min
South African regulators admit they're on the back foot against bulk-compounded and black-market weight-loss jabs, and Belgium refuses to reimburse Mounjaro for obesity. A JAMA Network Open study finds about half of early Wegovy pill starters were new to GLP-1s.
Listen
Show notes
South African regulators admit they're on the back foot against bulk-compounded and black-market weight-loss jabs, and Belgium refuses to reimburse Mounjaro for obesity. A JAMA Network Open study finds about half of early Wegovy pill starters were new to GLP-1s.
In this episode
- SA regulators struggle to control illegal weight-loss jabs — Daily Maverick
“But some pharmacies produce large quantities without that evidence, Sahpra chief executive Boitumelo Semete-Makokotlela told Bhekisisa. This means “you’re not compounding, you are manufacturing”, which requires a good manufacturing practice licence that compounding pharmacies do…”
- Belgium Rejects Reimbursement for Mounjaro in Obesity Treatment | NAVLIN DAILY — NAVLIN DAILY
“Belgium’s Health Minister Frank Vandenbroucke decided against reimbursing Eli Lilly’s Mounjaro (tirzepatide) for obesity treatment, citing budget and medical concerns, stressing that obesity needs more than just medication—it requires support from dietitians, psychologists, and…”
- Oral Semaglutide Uptake Near Injectable Levels Within 3 ... — AJMC
“Overall, 53.0% of oral semaglutide initiators had no GLP-1 RA use in the prior 12 months. The most common prior exposures were injectable semaglutide (28.9% of all oral semaglutide initiators) and injectable tirzepatide (27.5%).”